Shionogi

News

ViiV ownership shifts as Pfizer sells its stake

Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.

News

Shionogi puts up to $600m behind BioVersys antibiotics

Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.

News

Shionogi aims to buy tobacco giant's pharma unit for $1bn

Shionogi has reached a $1.04bn agreement to buy Torii, the pharma subsidiary of Japan Tobacco, as it tries to meet an ambitious sales target.

News

Shionogi gets approval in Japan for ADHD digital therapeutic

Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator.

News

Maze gets new Pompe partner after FTC blocks Sanofi deal

Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.

News

Shionogi takes Akili’s ADHD digital therapy to Japan

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype

ViiV ownership shifts as Pfizer sells its stake

Shionogi puts up to $600m behind BioVersys antibiotics

Shionogi aims to buy tobacco giant's pharma unit for $1bn

Shionogi gets approval in Japan for ADHD digital therapeutic

Maze gets new Pompe partner after FTC blocks Sanofi deal

Shionogi takes Akili’s ADHD digital therapy to Japan

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Shionogi

Editor's Picks